Pulmonx (NASDAQ:LUNG – Get Free Report) and P3 Health Partners (NASDAQ:PIII – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.
Analyst Recommendations
This is a breakdown of current ratings for Pulmonx and P3 Health Partners, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulmonx | 1 | 2 | 4 | 0 | 2.43 |
| P3 Health Partners | 1 | 2 | 1 | 0 | 2.00 |
Pulmonx presently has a consensus target price of $5.58, indicating a potential upside of 339.63%. P3 Health Partners has a consensus target price of $14.00, indicating a potential upside of 23.78%. Given Pulmonx’s stronger consensus rating and higher probable upside, equities analysts clearly believe Pulmonx is more favorable than P3 Health Partners.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulmonx | $90.50 million | 0.59 | -$54.00 million | ($1.30) | -0.98 |
| P3 Health Partners | $1.46 billion | 0.06 | -$147.95 million | ($38.60) | -0.29 |
Pulmonx has higher earnings, but lower revenue than P3 Health Partners. Pulmonx is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Pulmonx has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.
Institutional & Insider Ownership
91.0% of Pulmonx shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 6.8% of Pulmonx shares are held by insiders. Comparatively, 10.9% of P3 Health Partners shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Pulmonx and P3 Health Partners’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulmonx | -60.09% | -92.94% | -39.80% |
| P3 Health Partners | -8.57% | -302.33% | -19.99% |
Summary
Pulmonx beats P3 Health Partners on 8 of the 14 factors compared between the two stocks.
About Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
About P3 Health Partners
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.
